Navigation Links
UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
Date:1/9/2013

Baltimore, MD (PRWEB) January 09, 2013

UPM Pharmaceuticals announced today that it has purchased and qualified a TA Instruments Q20 Auto MDSC (Differential Scanning Calorimeter), and a TA Instruments Q50 TGA (Thermogravimetric Analyzer). These pieces of equipment greatly enhance the formulation development company’s ability to provide comprehensive pre-formulation studies, as well as support analytical testing of challenging formulations such as poorly soluble compounds.

UPM’s President, Jim Gregory, said, “UPM sees these new pieces of analytical equipment combined with our already highly qualified and experienced analytical team as a powerful combination for our clients who are trying to make the best and most cost effective decisions about investment of precious research funds. And further is looking for a partner that can perform the latest and best analysis with the most reliable equipment available in the pre-formulation stage of development.”

UPM Pharmaceuticals®, Inc. is a Baltimore-based contract development and manufacturing organization providing customized formulation development, manufacturing, and analytical services to pharmaceutical, biotechnology, academic, and veterinary clients.

Fully appreciating that time-to-market is critical, UPM offers remarkably flexible, affordable, and rapid outsourcing services designed to meet clients’ specific development and manufacturing needs. Their clients represent both small and large companies within the pharmaceutical and biotechnology industries, and academic institutions who have a focus on clinical studies.

About UPM Pharmaceuticals

UPM Pharmaceuticals, Inc. is a Baltimore-based, independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. They provide high quality pharmaceutical drug development services including formulation development, cGMP manufacturing, analytical methods development and stability testing. They are characterized by the quality, speed and thoroughness with which they complete all their projects. UPM’s clients enjoy service that is customized and fast with total quality management characteristic of a customer-focused business. Their history includes successful collaborative interactions with virtual to multi-million dollar companies providing them with customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets.

To learn more about UPM, please visit the Web site at http://www.upm-inc.com/

UPM Pharmaceuticals is a registered U.S. trademark.

Read the full story at http://www.prweb.com/releases/upm-inc/formulation-development/prweb10301311.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
2. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
3. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
4. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
5. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
6. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
7. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
8. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Oxford Gene Technology ... SureSeq™ NGS panel range with the launch of the SureSeq ... study of variants in familial hypercholesterolemia (FH). The panel delivers ... on a single small panel and allows customisation by ,mix ... all exons for LDLR , P C ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... in the World Technology Awards. uBiome is one of just six company finalists ... categories. , In addition to uBiome, companies nominated as finalists in this year’s ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selector™ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we ... of recovery so we need to do it well. Inadequate sleep levels have been ... blood pressure, stroke, diabetes, and even cancer. Maybe now is the best ... that could help them to manage their sleep quality? ... ...
Breaking Biology News(10 mins):